Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained

"Jefferies framed Gilead as one of the best-positioned large-cap biotechs available today, pointing to a clean intellectual-property runway, high operating margins, and operating leverage from overlapping franchises as the core investment thesis. With no major loss of exclusivity until 2036, the company has an unusually long period of predictable cash generation ahead of it, which gives management room to invest in pipeline and return capital to shareholders simultaneously."

"For Amgen, Jefferies was not dismissive - the firm acknowledged that near-term execution has been excellent - but concluded that a 35% run-up has left the stock fairly valued at current levels. With Jefferies' $350 target sitting below where Amgen currently trades, the Hold is effectively a signal to wait for a better entry point rather than chase the momentum."

"JPMorgan's reaffirmation on Oric came after shares dropped following unrelated competitor news, with the firm viewing the competitor-driven dip as unjustified given differentiated oncology pipeline data supporting the company's investment thesis and long-term value proposition."

Jefferies initiated coverage on Gilead Sciences with a Buy rating and $180 price target, citing clean intellectual property runway extending to 2036, high operating margins, and operating leverage from overlapping franchises. The firm assigned Amgen a Hold rating with a $350 price target, acknowledging strong execution but noting a 35% stock run-up has priced in near-term gains, suggesting investors wait for better entry points. JPMorgan maintained its Overweight rating on clinical-stage oncology company Oric Pharmaceuticals following a 16% pullback, viewing the decline as unjustified given the company's differentiated oncology pipeline data and unrelated competitor news driving the selloff.

Read at 24/7 Wall St.